SEBI refuses to take note of price manipulation in Transgene Biotek – Part II  

March 11, 2014

Did Transgene Biotek insiders use structured GDRs as an end game through price manipulation and motivated announcements? We will never know because SEBI refuses to investigate

Moneylife Digital Team

On Monday, Moneylife pointed out, several shareholders of Hyderabad-based Transgene Biotek Ltd are crying foul () over the alleged misuse of global depository receipts (GDRs)—a financial instrument used to raise capital overseas, and several “well-timed” announcements by the company.

To read more on this click here